Market Intelligence, Clinical Progress, and High-Purity Reagents for Squamous Cell Carcinoma and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD109 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD109 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD109 Products |
| Gene Delivery | CD109 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD109 Products |
| Benchmark Ab | Anti-CD109 (Sequence of clinical-stage clone) Recombinant positive control. |
View CD109 Products |
| Validator | CD109 siRNA Set For knockdown verification. |
View CD109 Products |
| Related Target A | TGFBR1 Co-receptor pathway partner; critical for TGF-beta signaling modulation assays. |
View TGFBR1 Products |
| Related Target B | EGFR Co-expressed with CD109 in squamous cell carcinomas; key for bispecific/combination screening. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Internalization kinetics in ADC development | HEK293 expressed CD109 ECD-Fc with native glycosylation for precise binding kinetics |
| Platelet/endothelial off-target toxicity screening | Cynomolgus and Mouse CD109 ortholog proteins available with >95% purity |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD109 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD109 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and CAR-T therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific glycosylated epitopes of CD109 to minimize off-target toxicity in normal tissues such as platelets and endothelial cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Academic Institutes, Biotech Startups | Squamous Cell Carcinomas, GBM | Internalization Assay (Need high-purity, native glycosylated ECD-Fc) |
| CAR-T / Cell Therapy | Translational Oncology Groups | Glioblastoma, Solid Tumors | Stable Cell Line Construction (Need high-titer Lentivirus Particles) |
| Bispecific Antibody | Biopharma Innovators | EGFR+ / CD109+ Tumors | Dual-Target Binding Assays (Need high-purity EGFR and CD109 proteins) |